ClinicalTrials.gg

Program

opemalirsen

Also written as “AZD2373 subcutaneous injection”, “AZD2373-Arm 1” and “AZD2373-Arm 2”.

Its studies are mostly in Renal Insufficiency, led by AstraZeneca.

Furthest: phase 2, since Jan 24, 20254 company-led studies, 1 open or runningNext primary completion: Oct 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca41 open or runningphase 2since Jan 24, 2025Feb 12, 2020Oct 4, 2027phase 2 · NCT06824987
  • Named in AstraZeneca’s own pipeline as opemalirsen, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04269031 · 30 enrolled · United States
  2. Apr 1, 2022Phase 1 study in Healthy VolunteersNCT05351047 · 24 enrolled · United States
  3. Jan 24, 2025Phase 2 study in APOL1-Mediated Kidney DiseaseNCT06824987 · 63 enrolled · United States, United Kingdom
  4. Jul 28, 2025Phase 1 study in Renal InsufficiencyNCT07154901 · 35 enrolled · United States

Ahead

  1. Oct 4, 2027Primary completion: phase 2 study in APOL1-Mediated Kidney DiseaseNCT06824987

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07154901Renal Insufficiency · United States1CompletedJun 15, 202635
NCT06824987APOL1-Mediated Kidney Disease · United States, United Kingdom2Active, not recruitingOct 4, 202763
NCT05351047Healthy Volunteers · United States1CompletedJul 6, 202324
NCT04269031Healthy Volunteers · United States1CompletedAug 31, 202130

How it is read

Names in the registry

  • “AZD2373 subcutaneous injection”, 2 entries
  • “AZD2373-Arm 1”, 1 entry
  • “AZD2373-Arm 2”, 1 entry
  • “Opemalirsen (AZD2373)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.